Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
ACS Medicinal Chemistry Letters – October 10, 2025
Source: OpenAlex
Summary
A breakthrough in psychedelic therapy reveals a novel psilocin-psilocybin cocrystal that enhances neuroplasticity and functional activity. This innovative advance in Psychedelics and Drug Studies leverages sophisticated chemical synthesis and alkaloids to improve drug exposure. Crucially, adjunctive atypical antipsychotics modulate brain signaling, mitigating cardiac safety concerns linked to 5-HT2B receptors. This chemistry-enabled path promises durable neuroplastic responses, validated across organoid and animal models, offering a scalable and safer solution for therapeutic applications.
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable psychedelic therapy with improved cardiac safety and durable neuroplastic responses across organoid and animal models.